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BACKGROUND: Plasma cell neoplasm (PCN) is a neoplastic plasma cell proliferation which includes solitary bone plasmacytoma (SBP), extramedullary 
plasmacytoma (EMP) and multiple myeloma (MM). 
Bartl classifies the degrees of PCN as low, intermediate 
and high. The aim of this study is to find the correlation 
between tumor suppressor gene p53 (TP53) expression and 
Ki-67 proliferation with Bartl malignancy degree of PCN. 
Therefore earlier PCN diagnostic method to prevent the 
development of PCN into MM can be found.
METHODS: Thirty-two PCN cases were classified into 
three groups based on Bartl’s degrees of malignancy. TP53 
and Ki-67 immunohistochemical staining were performed 
on samples and the percentage of positivity was evaluated.
RESULTS: The Bartl’s low degree of malignancy was 
found in 10 MM cases (31.2%), intermediate degree in 
Abstract 5 SBP cases  (15.6%) and high in 2 SBP and EMP cases (6.2%). TP53 expression was obtainable at 4% of low, 
16% of intermediate and 10% of high degree. There was a 
significant   difference   between  TP53  expression  in low 
and  intermediate  degree (p=0.004).  Mean  proliferation 
index  of  Ki-67 was 57% in low,  44.6% in  intermediate, 
and  32.6% in  high  degree. There  was  no  significant 
difference  of  Ki-67  proliferation indexes  among  the 
group  (p=0.339).
CONCLUSION: Increasing expression TP53 was in accord 
with Bartl’s degrees of malignancy, especially in low and 
intermediate degree, but there was no significant difference 
between Ki-67 proliferation index and Bartl’s degrees of 
malignancy.  
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Bartl classification
Indones Biomed J. 2017; 9(1): 35-42
Introduction
World Health Organization (WHO) classifies plasmacytoma 
into a neoplastic plasma cell without any infiltration to 
the bone marrow, including Solitary Bone Plasmacytoma 
(SBP), Extramedullary Plasmacytoma (EMP), and abnormal 
plasma cells (myeloma cells) build up in the bone marrow 
including Multiple Myeloma (MM).(1-3) More than 80% 
EMP developed in upper respiratory tract which has many 
lymphoid tissues and 17-33% grow into MM.(4-6)
 MM is classified into six cell types due to its size, 
cytoplasmic structure and the nucleus configuration. The 
classification is also associated with the prognosis degrees, 
which can be divided into low (40 months survival), medium 
(20 months survival) and high malignancy degree (8 months 
survival).(7)
 SBP can develop into MM in the average of 21 
months.(1,3) Around 65-84% SBP develops into MM in 10 
years, and 65-100% of them grows in 15 years. EMP has 
100% of 5-year-survival-rate, and 70% of 10-year-survival-
rate. Those who developed into MM had 70% of 5-year-
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survival-rate, compare to 33% patients with SBP.(8,9)  MM 
prognosis was worse with the mean of 3-4 years, and most 
of them were less than six months. Plasma cell neoplasm 
(PCN) prognosis was affected by age, tumor size, and 
location.(1,3)
 The development of myeloma comes from 
premalignant stage known as monoclonal gammopathy 
of unknown significance (MGUS) and become MM in 
the suitable microenvironment in bone, soft tissues and 
bone marrow. Until now, the development from MGUS to 
MM cannot  determine  as  predicting factor.(10) Genetic 
changes, such as oncogene activation and tumor suppressor 
gene mutation, clinically affect the aggressivity of MM. 
Tumor suppressor gene p53 (TP53) has a role in genomic 
stability and cell cycle.(5) Mutation of this protein in locus 
17p13 was  found in 5-10% myeloma cases (11), suggested 
that p53 protein could be used as a clinical prognostic 
marker (6). 
 The correlation between cluster of differentiation 
(CD)56 and TP53 to Mindbomb E3 ubiquitin-protein 
ligase 1 (MIB-1), in intramedullary and extramedullary 
lesion  progression  in  MM  formation was  found, but 
CD56 expression difference between EMP and MM was 
not.  TP53  expression  and  proliferation  activity, the MIB-
1, were correlated with tumor aggressivity.(12) A study 
showed  that  microvascular  density  and  Ki-67 staining, as 
a  marker  of  proliferation activity, were significantly higher 
in untreated  plasmacytoma  patients. The expression  of 
Ki-67 was correlated with PCN infiltration.(6,10) It might 
be the reason why the expression of TP53 and Ki-67 could 
be used for progressivity and prognosis marker in PCN.
(5,6,13-16) Diagnosis and staging of PCN were determined 
by clinical finding, radiologic (lesion found in soft tissues, 
bone, or bone marrow), and histopathologic data.
 The aim of this study is to find the correlation 
between TP53 expression and Ki-67 proliferation with 
Bartl malignancy degree of PCN. Therefore earlier PCN 
diagnostic method to prevent the development of PCN into 
MM can be found.
Methods
Institutional approval (Health Research Ethics Committee 
Faculty of Medicine Universitas Indonesia, #370/UN2.
F1.ETIK/2015) was taken prior to the study. The clinical 
data was obtained from RSCM medical record.  Damaged 
samples block were excluded. Samples were determined as 
SBP, EMP or MM based on WHO Classification of Tumours 
of Haematopoietic and Lymphoid Tissues.(3)
Histopathologic Slides Reexamination
The morphological classification using Bartl`s 
morphological  variants  was performed. After the 
overview, 2-10 power fields were chosen from slides. Bartl 
classifies six histologic types: (1) Marschalko, (2) small 
cell, (3) cleaved, (4) polymorphous, (5) asynchronous, 
and (6) blastic. The subtypes were determined based on 
the cell type that  mostly counted in slides and the highest 
malignancy degree. These  six subtypes  then  would  be 
grouped into low (Marschalko and small cell), medium 
(cleave, polymorphous and asynchronous), and high degree 
malignancy (blastic).
 
TP53 and Ki-67 Immunohistochemical Expression
The sections were cut from paraffin blocks, and the routine 
immunohistochemical methods were used to detect TP53 
and Ki-67 protein. TP53 protein (DO-7) (Leica Biosystem, 
Newcastle, UK) and Ki-67 primer monoclonal antibody 
(Biocare Medical, Concord, USA) were used. 
 Horseradish peroxidase (HRP) labeled TrekAvidin, 
phosphate-buffered saline (PBS) washing, and 
diaminobenzidine (DAB) was added to the slides. 
The slides were stained with Mayer hematoxylin 
(Biocare Medical, Concord, USA) before sequentially 
washed with running water, saturated lithium 
carbonate (5% in aqua dest) and another running water. 
A series of increasing alcohol concentrations were added to 
dehydrate the slides, and for clearing, xylol was also added. 
Finally, slides were covered with Entellan® (Merck 
Millipore, Wisconsin, USA) and glass cover. Colon 
adenocarcinoma tissue was used for TP53 positive control, 
and tonsil tissue was used for Ki-67 positive control. 
Negative control was prepared using the same procedures 
but with no primer antibody.
TP53 and Ki-67 Expression
Specimens’ digital photos were taken using Leica ICC 50 
HD microscope (Leica Microsystems, Wetzlar, Germany), 
and brown-stained nuclei were counted at about 300 cells 
using ImageJ® software (NIH Image, Bethesda, USA). The 
numeric variable was applied with no cut off.
The study was a retrospective cross-sectional using all 
cases of intramedullary and extramedullary plasma cell 
tumor, especially in bone or soft tissues which were 
recorded between 2011-2014 in Department of Pathology 
Anatomy, Faculty of Medicine, University of Indonesia/
dr. Cipto Mangunkusumo Hospital (FKUI/RSCM), Jakarta. 
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Statistical Analysis
The statistical analysis was performed by SPSS 12 (IBM 
SPSS, New York, USA). Shapiro-Wilk test showed that the 
samples were not normally distributed, so the correlation 
between TP53 and malignancy degree was utilized with 
Kruskal-Wallis non-parametric test and Mann-Whitney 
post hoc test, while the correlation between Ki-67 and 
malignancy degree was performed using unpaired numeric 
variable hypothesis test, one-way ANOVA, continued with 
Bonferroni post hoc test. Correlation between TP53, Ki-67, 
and age was performed using Spearman correlation test, 
with significance p<0.05.
Results
Table 1. The  characteristics  of  the  study  group  from  data 
2011-2014.
Samples Characteristics
A total of 32 cases (16 men and 16 women) were reevaluated 
during the study period. In both genders was found that 
most cases are the low-grade malignancy. There was no 
correlation between sex and malignancy (p=0.198). The 
cases were distributed in subjects between 21-72 years old, 
most of them were in their 50s (13 cases). Most malignancy 
situations were found in bone (15 cases) (Table 1). Five cases 
were found to have multiple or recurrent lesions, where 4 of 
them were categorized as SBP and one case as MM. Two 
cases were found as repetitive with low malignancy degree, 
1 case recurrent with medium malignancy degree and 2 
cases with high malignancy degree.
 Based on malignancy degree (Bartl classification), 
we found 10 cases (31.3%) of Marschalko subtype, 8 cases 
(25%) of small subtype, 4 cases (12.5%) of cleaved subtype, 
2 cases (6.2%) of polymorphous subtype, 3 cases (9.4%) 
of asynchronous subtype and 5 cases (15.6%) of blastic 
subtype (Figure 1).
 Other histological images were also found in 
reevaluation, including 19 “blood lake” cases (59.3%), 11 
Dutcher body cases (34.3%) and 3 amyloid cases (9.3%). 
Diagnosis showed most MM was found in low malignancy 
degree (10 cases; 31.2%), most SBP found in low malignancy 
degree (7 cases; 21.8%), and most EMP found in medium 
and high malignancy degree (2 cases; 6.2%) (Table 1).
TP53 Expression and Ki-67 Proliferation Activity
It was found that 9 cases were negative or no positive 
stained nuclei TP53 expression. Eight cases showed to 
have low malignancy degree, which was found in bone and 
bone marrow. Meanwhile, one case of medium malignancy 
degree was found in soft tissue. 
 Shapiro-Wilk test showed that data were not normally 
distributed. Kruskal-Wallis test showed a significant 
difference between malignancy degrees (p<0.05), while 
Mann-Whitney post hoc test showed a significant difference 
between low and medium malignancy degree, but no 
difference between high and medium (p=0.386) or low 
(p=0.101) malignancy degree.
Low Medium High
Gender
     Male 11 3 2 16 (50%)
     Female 7 6 3 16 (50%)
Age
     21-30 1 0 0 1 (3.1%)
     31-40 1 1 0 2 (6.3%)
     41-50 2 3 1 6 (18.8%)
     51-60 9 2 2 13 (40.6%)
     61-70 5 3 1 9 (28.1%)
     >70 0 0 1 1 (3.1%)
Location
Bone Marrow 9 2 0 11 (34.4%)
Bone
     Thoracic 3 1 0 4 (12.5%)
     Femur 2 1 2 5 (15.6%)
     Humerus 0 3 0 3 (9.4%)
     Lumbal 1 0 0 1 (3.1%)
     Clavicula 1 0 0 1 (3.1%)
     Mandibula 1 0 0 1 (3.1%)
Extramedullary
     Head&Neck 1 1 1 3 (9.4%)
     Thorax 0 0 1 1 (3.1%)
     Intracranial 0 1 1 2 (6.3%)
Diagnosis
     MM 10 2 1 13 (40.6%)
     SBP 7 5 2 14 (43.8%)
     EMP 1 2 2 5 (15.6%)
Total 18 (56.3%)
9 
(28.1%)
5 
(15.6%)
32 
(100%)
Demographic 
Data
Malignancy Degree
Total (%)
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Discussion
 Menawhile, the Shapiro-Wilk test showed a normally 
distributed data for Ki-67 staining expression. No significant 
difference was found in this staining.
 
TP53 Expression and Ki-67 Proliferation Index 
Determination on SBP and EMP
The differences of TP53 and Ki-67 expression were 
observed in different malignancy degree for SBP and EMP 
cases, and were found no differences (p=0.129) (Table 2B).
TP53 Expression and Ki-67 Proliferation Index 
Determination on PCN Diagnosis
We found high expression of TP53 (median 15%; interval 
0-55%), and Ki-67 proliferation index (mean 42.5%) in 
SBP, and low expression of TP53 (median 9%; interval 
 A B   C   
D   E   F   
Figure 1.  Bartl’s PCN classification based on malignancy degree. A: marschalko subtype; B: small cell subtype; C: cleaved subtype; 
D: polymorphous subtype; E: asynchronous subtype; F: blastic subtype. (Magnification: 400x).
Median Interval (min-max) p Mean±SD p
Low 18 4 0-29 0.010 57±25.32 0.339
Medium 9 16 0-55 44.67±21.09
High 5 10 6-42 32.6±5.12
TP53 Ki-67
Table 2A. Result of TP53 and Ki-67 expression based on to Bartl classification on SBP, EMP and MM.
Malignancy degree n
Table 2B. The difference of TP53 expression based on to Bartl classification on SBP and EMP.
Median Interval (min-max) p
Low 8 5 0-29 0.129
Medium 7 16 0-55
High 4 19.5 6-42
Malignancy degree n
TP53
The prevalence of hematopoietic neoplasm in the USA 
recorded 20,000 cases in 2010. In the same year, Indonesia 
Cancer Registry found 0.43% (107 of 24,781 total 
neoplasms) cases of hematolymphoid solid tumor. There 
were no gender differences for hematopoietic neoplasm. 
PCN was found only 1% from all neoplasm and about 10% 
from hematopoietic neoplasm, majority in patients’ age 
0-37%) and Ki-67 proliferation index (mean 30.67%) in 
MM cases (Table 3). There was no correlation between TP53 
expression and Ki-67 expression, as well as no correlation 
between both to age (p>0.05).
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1, and 60% for stage 3. This happened because of the low 
level  of  proliferation in neoplastic plasma cell. Around 
13% positive BJ protein was found in SBP cases.(23)
 International Myeloma Working Group (IMWG) 
recommended urine and serum monoclonal protein 
routine test for any suspect B-cell neoplasm and MM. Any 
monoclonal finding without PCN signs will be diagnosed as 
MGUS.(24) Patients with >10% bone marrow plasma cell 
without any >30 g/L M protein finding in urine/serum will 
be diagnosed with asymptomatic myeloma or smoldering 
myeloma, which is biologically similar to MGUS, and 
have to be strictly followed up due to its fast progression to 
MM. There was no correlation between surface marker, M 
component, morphologic classification, and clinical stage in 
MM and MGUS.(7)
  We  didn’t  exclude  11  cases  from  bone  marrow 
because they have supported clinical data including 
monoclonality, positive BJ protein, immunohistochemistry 
CD38+ and CD138+, CD19- and CD3- as a compared 
diagnosis for PCN.(3,15,25)
 Generally, all neoplastic plasma cell histological 
images were all similar. However, each malignancy degree 
has their unique characteristic, such as mild until medium 
plasma cell dysplasia, increasing cell size, pleomorphism, 
increasing N:C ratio, having more than one nuclei and 
mitosis, or even having a giant plasma cell with many 
nuclei. Basophilic or eosinophilic cytoplasm with flaming 
peripheral blood smear could have one or more cytoplasm 
inclusions. Dutcher body could also be seen as nuclear 
inclusion images.(3,18) Zuo, et al., described “blood cell 
lake” as one image found in plasmacytoma.(19) Amyloid 
could be found in 10-15% cases of plasma cell myeloma 
in bone marrow or bone.(3,18) Due to Bartl classification 
(26,27), this study showed 19 cases (59.3%) with “blood 
cell lake” histological image, 11 cases (34.3%) with 
Dutcher body and 3 cases (9.3%) with amyloid. It is less 
if compared to Zuo's study where 37.5% “blood cell lake,” 
12.5% Dutcher body and 18.8% amyloid deposition.
 Our population showed 18 cases (56.3%) of low 
malignancy degree, 9 cases (28.1%) of medium degree and 
5 cases (15.6%) of high degree. The most number subtype 
we found was Marschalko subtype (10 cases), followed 
by small cell subtype (8 cases), both were low malignancy 
degree, same as a study by Jayashankar, et al., who found 
Marschalko as the most frequent subtype.(28) The nucleolus 
is suggested as the most significant characteristic to 
determine malignancy degree (29), but irregular cytoplasm 
image and plasma cell anisocytosis should be noticed as 
well. Intra-observer variation was 33%, so the best way 
Ki-67
Median (%) Interval (min-max) Mean (%)
SBP 14 15 0-55 43
EPM 5 10 0-29 34
MM 13 9 0-37 31
Diagnosis n
TP53
Table 3. Result of  TP53 and Ki-67 expression on PCN. 
between 55-64 years old.(1-3) PCN are the diseases where 
the abnormal plasma cells or myeloma cells form tumors in 
the bone or soft tissue.(4)  In this study, PCN cases have 1:1 
ratio between men and women and most cases were found 
in fifth decades of life. Previous study found no prevalence 
difference between men and women (3), while another 
study found a 1.8:1 ratio differences (1). Dores, et al., stated 
a 2:1 ratio in men vs. women with SBP, 2.6:1 for EMP, and 
1.5:1 for MM.(9) It was also found that predominant men 
have 6:1 ratio to women.(17)
 Our study found MM cases in age 40-67 with median 
59 years old, SBP cases in age 21-70 years old with median 
52 years old, and EMP cases in age 48-72 years old with 
median 61 years old. Mean age for SBP and EMP in WHO 
study was 55 years old with 2:1 ratio of men vs.women.(1,3) 
Meanwhile, other studies found that median age for MM is 
65 years old (3,7,18), for SBP is 60 years old and for EMP 
55 years old (8). Overall, most cases in our study were found 
in fifth decades of life, while other studies found their cases 
in sixth or seventh decades of life. Accordance to WHO, 
SBP most frequently found in the femur, meanwhile EMP in 
the head-neck region.(3,18,19) Two EMP cases were found 
in intracranial, both in lobus frontalis, with medium and 
high malignancy degrees. Cranial base is the most frequent 
location for intracranial plasmacytoma.(20)
 Clinically, 26 cases in our study showed 
hemoglobin level between 5.4-15.2 mg/dL. Anemia 
could happen in PCN, although there were other factors 
like chronic illness can play a role.(3) Al-Farsi also 
reported normochromic anemia in 75% of cases, due 
to increased plasma cell in peripheral blood test.(21) 
In monoclonality determination, 12 cases from 17 were 
found as monoclonal. Bence Jones (BJ) Protein test only 
performed in 4 cases and found one positive case. In urine 
or serum test was found 99% monoclonality and protein M, 
and 75% of the cases were positive for BJ protein. Kidney 
impairment  could  be  induced  by  hypercalcemia  and  rarely 
by amyloidosis.(3) Pratt, who performed a conventional 
test, only found 40% cases with clonal abnormality, and 
only 20-30% were found on diagnosis.(22) Due to Durie 
& Salmon staging, we found only 20% frequency for stage 
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Figure 2. TP53 staining on PCN. A: TP53 positive control, with brown-stained nuclei, considered as positive; B: negative control, no 
brown staining found, considered as negative and/or 0%; C: low malignancy degree of TP53 staining image (0%); D: medium degree 
(37%); E: high degree (42%). (Magnification: 100x).
Figure 3. Ki-67 staining on PCN. A: Ki-67 positive control, with brown-stained nuclei, considered as positive; B: negative control, no 
brown staining found, considered as negative; C: low malignancy degree Ki-67 staining image (10%); D: medium degree (35%); E: high 
degree (50%). (Magnification: 400x).
to predict this character was to count the plasma cell. 
Our data showed most cases were in low malignancy 
degree compare to the medium and high degree, either in 
MM (10:2:1), SBP (7:5:2) and EMP showed 1:2:2 ratio. 
It means that we can not use Bartl classification to predict 
the malignancy progression become MM, since MM was 
mostly found in low malignancy degree.
 We observed the recurrence cases and found 5 cases 
with recurrent time between 1-22 months. They were 3 with 
low malignancy degree, 1 with medium degree and 2 with 
high degree. One SBP case developed into MM with low 
malignancy degree. Four recurrent cases found in bone, 
without any progression to MM and have no neoplastic 
plasma cell in bone marrow. Lorsbach stated that SBP has a 
higher risk to develop into MM (65-84%) in 10 years, and 
(65-100%) in 15 years.(8) Another study showed that 60% 
SBP cases and 20% EMP cases progressed into MM in three 
years.(30,31) No plasmacytoma patients died or developed 
into myeloma in about 50 months.(17)
 Table 2 showed TP53 and Ki-67 expression in this 
study. TP53 was significantly different in each malignancy 
stages (p=0.01). TP53 expression was correlated with 
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intramedullary and extramedullary lesion development to a 
higher degree.(12) A lot of p53 mutations in higher level 
and aggressive MM.(6) IMWG stated that a high number 
of neoplastic plasma cell in peripheral blood smear and its 
proliferation activity in bone marrow could be a risk factor 
for immediately MM development. Until now, there were 
no fixed methods and sensitive cytometer devices used 
globally.
 A study claimed that b2-microglobulin and Ki-67 
could  be  used  for  plasma  cell  proliferation  in  stage 1 
plasmacytoma due to Durie & Salmon (31), but our study 
found no difference of Ki-67 expression in each stage. In 
MM, proliferation activity was correlated to angiogenesis, 
and Ki-67 index was increased in the region with more 
vessels. This showed a correlation between Ki-67 expression 
and angiogenesis. The result of variant could be found 
due to different methods of study, patients’ characteristic, 
population, ethnicity, and environment.(16) Girino also 
found no correlation in Ki-67 expression in MM cases.(32) 
More observation is needed to find the progression of MM 
cases in this study.
 We found no difference between TP53 and KI-67 
expression with malignancy degrees (Figure 2, Figure 3) or 
with age and other clinical signs. TP53 and Ki-67 expression 
were high in SBP and low in MM (Table 3). TP53 together 
with clinical stages data, Bartl histological degree was 
correlated with survival rate.(33) TP53 expression data 
can be used as a survival rate factor especially in bone 
marrow biopsy. Our study showed that TP53 and Ki-67 
expression combined with Bartl classification were not 
enough to predict the development plasmacytoma into MM. 
Completed clinical data and stages information were needed 
to predict the myeloma progression. We also suggest there 
were other pathogenesis pathways which play roles in this 
progression, such as apoptosis.
 SBP and EMP therapies were given for younger 
patients (<65 years old), similar to MM, using high doses 
of chemotherapy combiner with autologous stem cell 
transplantation (ASCT). Maintenance therapies to improve 
the life quality are steroid, interferon-a with or without 
thalidomide. Only progressed patients will continue 
the therapies. Asymptomatic patients won’t receive any 
therapies but will be observed for the disease progression.
(18,19) We didn’t observe any therapies in this study so we 
couldn’t know the TP53 and Bartl classification correlation 
to therapy responds. 
 Plasmacytoma survival rates depend on malignancy 
type and degrees. We have no sufficient data about our 
patients’ survival rate, but we recorded only one patient 
died after a month ambulatory. We hope that this study can 
give more information that low malignancy grade (Bartl 
classification) MM has a better survival rate, and clinicians 
need to reckon Ki-67 and angiogenesis parameters for the 
patients.
 The limitations of this study were the small number 
of samples and some of the samples observations only 
performed in small specimens of bone marrow. We also 
have very limited clinical data and therapies follow up due 
to uncompleted medical records. We suggest an integrated 
bone marrow observation for SBP and EMP suspected 
patients to confirm that has not developed into MM. 
Periodical check in recurrent and mortality rates also need 
to be observed to have a valid prognostic study.
Increasing expression TP53 is in accordance with Bartl’s 
degrees of malignancy, especially in low and intermediate 
degree but there is no significant difference of Ki-67 
proliferation indexes with Bartl’s degrees of malignancy.
Conclusion
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